Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab

Jeong Seok Lee, Yeong Wook Song, Tae Hwan Kim, Won Tae Chung, Seung Geun Lee, Sung Hwan Park, Gwan Gyu Song, Dae Young Yu, Stephen Xu, Eun Young Lee

Research output: Contribution to journalArticle


Background/Aims: For patients with ankylosing spondylitis (AS), golimumab has consistent efficacy in controlling disease activity over 5 years but its benefit in preventing radiographic progression was less clear at 4 years. To predict radiographic progression, we analyzed the baseline characteristics of AS patients in a Korean population. Methods: Sixty-eight Korean patients with AS participated in the phase 3, multi-center, randomized, placebo-controlled, double-blind trial (GO-RAISE) which has previously been described. Baseline modified stoke AS spine score (mSASSS) and change in mSASSS from baseline (ΔmSASSS) until week 208 were analyzed in the Korean patients enrolled in the GO-RAISE study. Results: Although Korean patients had lower baseline mSASSS compared to non-Korean patients and received active management, radiographic progression was not prevented. Korean patients who did not undergo radiographic progression of spinal lesions of AS were younger and had shorter symptomatic duration, lower Bath AS functional and metrology indices, better chest expansion, and lower baseline mSASSS. The baseline mSASSS and ΔmSASSS were positively correlated in Korean AS patients (p < 0.001). Radiographic progression was more prevalent (80.0%) when baseline mSASSS > 10 and less common (13.0%) with baseline mSASSS = 0. Conclusions: In Korean AS patients, radiographic progression of the spine after 4 years was predicted effectively by the initial severity of the spinal lesion(s) in patients treated with golimumab.

Original languageEnglish
Pages (from-to)622-628
Number of pages7
JournalKorean Journal of Internal Medicine
Issue number3
Publication statusPublished - 2018 May 1



  • Ankylosing
  • Disease progression
  • Golimumab
  • Spondylitis

ASJC Scopus subject areas

  • Internal Medicine

Cite this